二仙汤加味联合揿针治疗围绝经期抑郁症的 临床疗效观察

Clinical Efficacy of Modified Erxian Decoction with Formula Combined with Pressing Needle in the Treatment of Perimenopausal Depression

摘要: 目的：观察二仙汤加味联合揿针治疗围绝经期抑郁症患者，其症状及内分泌指标改善的临床疗效。方法：研究对象选取为2023年09月~2024年09月我院妇产科门诊就诊的66例围绝经期抑郁症患者，随机分为观察组和对照组各33例，对照组患者口服芬吗通常规治疗，观察组患者采用二仙汤加味联合揿针治疗，对比两组患者治疗前后的临床症状改善情况及相关内分泌指标改善情况。结果：治疗后观察组患者在情绪低落、焦虑不安、胸胁胀痛、胸闷嗳气、腰膝酸软、记忆力减退、头晕耳鸣、失眠多梦等症状的改善上显著优于对照组，差异具有统计学意义(P < 0.05)；治疗后与治疗前比较两组患者HAMD评分均下降，差异有统计学意义(P < 0.05)，组间比较治疗后观察组与对照组差异有统计学意义(P < 0.05)。并且观察组的总有效率优于对照组，差异有统计学意义(P < 0. 05)；治疗后与治疗前比较两组患者改良Kupperman评分均下降，差异有统计学意义(P < 0.05)，组间比较治疗后观察组与对照组比较差异有统计学意义(P < 0.05)。并且观察组的总有效率优于对照组，差异有统计学意义(P < 0.05)；治疗后血清性激素FSH、LH及E2水平改善情况显著优于对照组，差异具有统计学意义(P < 0.05)。结论：二仙汤加味联合揿针能够调节围绝经期抑郁症患者性激素水平，有效地改善围绝经期抑郁症患者的临床症状及抑郁情况，与常规激素治疗相比更具优势，值得在临床上推广和应用。

Abstract: Objective: To observe the clinical efficacy of modified Erxian Decoction combined with acupressure in treating perimenopausal depression patients, focusing on symptom improvement and endocrine index changes. Methods: A total of 66 perimenopausal depression patients who visited the gynecology outpatient department of our hospital from September 2023 to September 2024 were selected as study subjects and randomly divided into an observation group and a control group, with 33 cases in each group. The control group received conventional oral treatment with fenamethol, while the observation group received modified Erxian Decoction combined with acupressure. The clinical symptom improvement and related endocrine index changes before and after treatment were compared between the two groups. Results: After treatment, the observation group showed significantly better improvement in symptoms such as low mood, anxiety, chest and hypochondriac pain, chest tightness and belching, soreness and weakness in the waist and knees, memory decline, dizziness, tinnitus, and insomnia with vivid dreams compared to the control group, with statistically significant differences (P < 0.05). The HAMD scores of both groups decreased after treatment compared to before treatment, with statistically significant differences (P < 0.05). The comparison between the observation group and the control group after treatment also showed statistically significant differences (P < 0.05). Additionally, the total effective rate of the observation group was superior to that of the control group, with statistically significant differences (P < 0.05). The modified Kupperman scores of both groups decreased after treatment compared to before treatment, with statistically significant differences (P < 0.05). The comparison between the observation group and the control group after treatment also showed statistically significant differences (P < 0.05). The observation group demonstrated a significantly higher overall response rate than the control group (P < 0.05), with statistically significant differences in the improvement of serum sex hormone levels (FSH, LH, and E2) post-treatment (P < 0.05). Conclusion: The modified Erxian Decoction combined with acupressure can regulate sex hormone levels in perimenopausal depression patients, effectively improving clinical symptoms and depressive conditions. Compared to conventional hormone therapy, this approach shows superior efficacy and is worthy of clinical promotion and application.